Vaping has become extremely versatile in life and thus chosen in numerous options of devices, counting to millions. However, especially among the on-the-go vapers, compact devices including vape pens ...
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.